Idelalisib monotherapy and durable responses in patients with relapsed or refractory small lymphocytic lymphoma (SLL)

被引：0
|
作者：
Gopal, A. [1 ]
Davies, A. J. [2 ]
Flinn, I. [3 ]
Ghia, P. [4 ,5 ]
Goy, A. [6 ]
Salles, G. [7 ]
Abella, S. [8 ]
Philip, B. [8 ]
Sorenson, B. [8 ]
Wagner-Johnston, N. [9 ]
机构：
[1] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[2] Univ Southampton, Canc Sci Unit, Salisbury, Wilts, England
[3] Sarah Cannon Res Inst, Hematol Malignancies Res Program, Nashville, TN USA
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] IRCCS Ist Sci San Raffaele, Milan, Italy
[6] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[7] Univ Lyon 1, Hosp Civils Lyon, Pierre Benite, France
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
245
引用
下载
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [31] A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    Long, Meixiao
    Woyach, Jennifer
    Pinilla-Ibarz, Javier
    Stephens, Deborah M.
    Cacovean, Alex
    Fiaz, Rana
    Goldberg, Zelanna
    Jagasia, Madan
    Finckenstein, Friedrich Graf
    Fardis, Maria
    Byrd, C.
    CANCER RESEARCH, 2021, 81 (13)
  • [32] A PHASE 2 STUDY OF THE BTK INHIBITOR IBRUTINIB IN GENETIC RISK-STRATIFIED RELAPSED AND REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
    Maddocks, K.
    Flynn, J. M.
    Andritsos, L. A.
    Awan, F.
    Woyach, J. A.
    Grever, M. R.
    Stefanos, M.
    Lynch, J.
    Johnson, A. J.
    Byrd, J. C.
    Jones, J. A.
    HAEMATOLOGICA, 2014, 99 : 522 - 522
  • [33] The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
    Nair, Kruti Sheth
    Cheson, Bruce
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 69 - 84
  • [34] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    HEMASPHERE, 2018, 2 (03):
  • [35] Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
    Cheah, Chan Yoon
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Forbes, Sheryl G.
    Oki, Yasuhiro
    Fowler, Nathan H.
    BLOOD, 2015, 125 (21) : 3357 - 3359
  • [36] ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan Mary
    Qiu, Lugui
    Paik, Jason C.
    Hilger, James D.
    Huang, Jane
    Tam, Constantine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Iyer, Swaminathan Padmanabhan
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 914 - 917
  • [38] Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
    Barrientos, Jacqueline C.
    FUTURE ONCOLOGY, 2016, 12 (18) : 2077 - 2094
  • [39] IDELALISIB MONOTHERAPY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA
    Li, J. J.
    Breuleux, M.
    Smith, C.
    Davies, A.
    HAEMATOLOGICA, 2016, 101 : 103 - 104
  • [40] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
    Woyach, Jennifer Ann
    Flynn, Joseph M.
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, Margaret
    Chase, Weihong
    Yang, Ying
    Lucas, David M.
    Sass, Ellen
    Waymer, Sharon
    Ling, Yonghua
    Jiang, Yao
    Phelps, Mitch A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345